This site is intended for healthcare professionals
News

Phase III COMBI-i study of PDR 001 + Tafinlar + Mekinist fails to meet primary endpoint in melanoma.- Novartis

Read time: 1 mins
Last updated:16th Mar 2021
Published:23rd Aug 2020
Condition: Metastatic Melanoma
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest